Celgene Co. (NASDAQ:CELG) Given Consensus Recommendation of “Hold” by Brokerages

Celgene Co. (NASDAQ:CELG) has been assigned an average recommendation of “Hold” from the twenty-two brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, nineteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $97.31.

CELG has been the subject of a number of research reports. Standpoint Research downgraded Celgene from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. BidaskClub raised Celgene from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cowen restated a “hold” rating and set a $102.00 price target on shares of Celgene in a research note on Tuesday, July 30th. Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a research note on Tuesday, July 23rd. Finally, Leerink Swann set a $115.00 price target on Celgene and gave the company a “hold” rating in a research note on Friday, November 1st.

In other Celgene news, insider Terrie Curran sold 11,338 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the transaction, the insider now directly owns 13,493 shares in the company, valued at approximately $1,325,957.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.39% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. First PREMIER Bank bought a new stake in Celgene during the third quarter valued at about $26,000. B & T Capital Management DBA Alpha Capital Management purchased a new stake in Celgene in the third quarter valued at about $28,000. Liberty Wealth Management LLC raised its stake in Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 200 shares during the last quarter. Massey Quick Simon & CO. LLC purchased a new position in shares of Celgene in the second quarter worth about $33,000. Finally, Lenox Wealth Advisors LLC purchased a new position in shares of Celgene in the third quarter worth about $37,000. Institutional investors and hedge funds own 71.66% of the company’s stock.

NASDAQ:CELG traded down $0.07 during mid-day trading on Monday, reaching $109.95. The stock had a trading volume of 851,864 shares, compared to its average volume of 4,355,211. The company has a market capitalization of $78.30 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 0.52 and a beta of 1.41. Celgene has a 1-year low of $58.59 and a 1-year high of $110.70. The stock’s 50 day simple moving average is $103.82 and its two-hundred day simple moving average is $97.24. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.89 and a quick ratio of 2.80.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 EPS for the quarter, topping the Zacks’ consensus estimate of $2.70 by $0.29. The business had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same period last year, the firm earned $2.29 earnings per share. Sell-side analysts anticipate that Celgene will post 10.7 EPS for the current fiscal year.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Understanding Options Trading

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.